Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

SKYTROFA® (Lonapegsomatropin-tcgd), The First Therapy Discovered for Pediatric Growth Hormone Deficiency

Acendis Pharma discovered SKYTROFA (lonapegsomatropin-tcgd) for the treatment of pediatric growth hormone deficiency.

It is the only once-weekly treatment applicable for patients with one year of age and older weighing at least 11.5kg having lack of growth due to insufficient secretion of endogenous Growth Hormone (GH).

SKYTROFA® (lonapegsomatropin-tcgd) is a weekly once prodrug designed to deliver somatropin over a one-week period. It is a single-use, prefilled cartridges are presented in nine dosage strengths thus allowing convenient dosing flexibility.

SKYTROFA should not be used in patients with acute critical illness after undergoing open heart surgery, abdominal surgery or multiple accidental trauma. Moreover, there is an increased risk of malignancy progression in patients with active malignancy when treated with somatropin. It also decreases the insulin sensitivity usually at higher doses.

SKYTROFA is the only FDA approved weekly once treatment commercially available in U.S for the growth harmone deficiency.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024